Erin Sloane's practice focuses on government and internal investigations and white collar criminal matters, with a concentration on Foreign Corrupt Practices Act (FCPA) and international anti-corruption issues. She has successfully represented both institutions and individuals in government investigations and prosecutions involving financial and accounting fraud, insider trading, wire fraud, and FCPA issues.
Ms. Sloane has conducted numerous cross-border corruption investigations in Asia, Eastern Europe, the Middle East and South America, and regularly appears before the US Department of Justice (DOJ) and Securities and Exchange Commission (SEC) in corruption-related investigations. She has successfully achieved multiple non-public DOJ and SEC declinations for clients in FCPA matters and has advised several prominent clients as they have worked to meet the terms of their publicly disclosed FCPA resolutions with the DOJ and SEC. Ms. Sloane also regularly counsels clients on challenging anti-corruption issues in numerous business contexts, including the development and implementation of effective anti-corruption compliance programs and corruption-related considerations in cross-border mergers, joint ventures and acquisitions.
In August 2019, the DOJ and SEC appointed Ms. Sloane as the independent FCPA compliance monitor for a German-based global healthcare company with a market cap of $24 billion. With this appointment, which is set to run for two years, she becomes one of only a handful of women awarded an FCPA monitorship in the past decade.